ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,469.30
0.39%
Dow Jones
39,112.16
-0.76%
US Dollar vs MXN
18.10565
-0.11%
Brent Oil
84.675
0.58%
Bitcoin
61,690.25
-0.18%
Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Ocular Therapeutix Inc (OCUL)

  7. Ocular Therapeutix Inc (OCUL) Noticias

OCUL

Ocular Therapeutix (OCUL)

Ocular Therapeutix Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:OCUL
FechaHoraFuenteTítuloSímboloCompañía
17/06/202415:12Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OCULOcular Therapeutix Inc
14/06/202408:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCULOcular Therapeutix Inc
13/06/202415:05GlobeNewswire Inc.Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR StudyNASDAQ:OCULOcular Therapeutix Inc
05/06/202406:30GlobeNewswire Inc.Ocular Therapeutix® to Host Investor Day on June 13, 2024NASDAQ:OCULOcular Therapeutix Inc
04/06/202416:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
04/06/202416:26Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:OCULOcular Therapeutix Inc
04/06/202415:05GlobeNewswire Inc.Ocular Therapeutix® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OCULOcular Therapeutix Inc
30/05/202416:17Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OCULOcular Therapeutix Inc
07/05/202415:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCULOcular Therapeutix Inc
07/05/202415:05GlobeNewswire Inc.Ocular Therapeutix™ Reports First Quarter 2024 ResultsNASDAQ:OCULOcular Therapeutix Inc
07/05/202415:01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:OCULOcular Therapeutix Inc
06/05/202419:16GlobeNewswire Inc.Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:OCULOcular Therapeutix Inc
06/05/202406:30GlobeNewswire Inc.Ocular Therapeutix™ to Present at Two Upcoming Investor ConferencesNASDAQ:OCULOcular Therapeutix Inc
03/05/202406:30GlobeNewswire Inc.Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024NASDAQ:OCULOcular Therapeutix Inc
01/05/202406:30GlobeNewswire Inc.Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024NASDAQ:OCULOcular Therapeutix Inc
11/03/202415:12Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:OCULOcular Therapeutix Inc
11/03/202405:39IH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:OCULOcular Therapeutix Inc
19/02/202408:00PR Newswire (US)AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic ConjunctivitiNASDAQ:OCULOcular Therapeutix Inc
15/02/202407:00GlobeNewswire Inc.Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial OfficerNASDAQ:OCULOcular Therapeutix Inc
14/02/202418:48Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OCULOcular Therapeutix Inc
13/02/202406:37GlobeNewswire Inc.Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMDNASDAQ:OCULOcular Therapeutix Inc
28/12/202315:17Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:OCULOcular Therapeutix Inc
18/12/202315:52Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:OCULOcular Therapeutix Inc
18/12/202315:01GlobeNewswire Inc.Ocular Therapeutix™ Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional SharesNASDAQ:OCULOcular Therapeutix Inc
14/12/202315:09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:OCULOcular Therapeutix Inc
13/12/202321:09GlobeNewswire Inc.Ocular Therapeutix™ Announces Pricing of Public Offering of Common StockNASDAQ:OCULOcular Therapeutix Inc
13/12/202318:07Dow Jones NewsStocks to Watch: Adobe, Amtech Systems, Ocular TherapeutixNASDAQ:OCULOcular Therapeutix Inc
13/12/202315:01GlobeNewswire Inc.Ocular Therapeutix™ Announces Proposed Public Offering of Common StockNASDAQ:OCULOcular Therapeutix Inc
16/11/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:OCULOcular Therapeutix Inc
08/11/202307:00GlobeNewswire Inc.Ocular Therapeutix™ to Present at Three Upcoming Investor ConferencesNASDAQ:OCULOcular Therapeutix Inc
 Showing the most relevant articles for your search:NASDAQ:OCUL

Su Consulta Reciente

TG
A19VPF
Belfius Bank
BIT
P21I35
NLBNPIT21I35 20240918 16...
LSE
JD1X
1x Jd
BIT
P21753
NLBNPIT21753 20351221 5....
NASDAQ
KPPC
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados